Catalyst Pharmaceuticals (FRA:CN2) Total Equity: €876.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CN2 Catalyst Pharmaceuticals Inc FRA:CN2
93 GF Score
Price €27.30
GF Value €20.73
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Catalyst Pharmaceuticals Total Equity?

Catalyst Pharmaceuticals FRA:CN2 93 Total Equity is €876.0 Mil as of Mar. 2026. GuruFocus rates FRA:CN2 with a GF Score™ of 93/100 and a GF Value™ of €20.73 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Catalyst Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was €876.0 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Catalyst Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Catalyst Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals Total Equity Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 183.05 283.60 355.69 694.89 814.95

Catalyst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 734.71 742.18 784.05 814.95 875.98
FRA:CN2
93GF Score
Catalyst Pharmaceuticals Inc FRA:CN2
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Catalyst Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Catalyst Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=942.798-127.853
=814.9

Catalyst Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=992.683-116.7
=876.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €876.0 Mil mean?
Catalyst Pharmaceuticals (FRA:CN2) has a Total Equity of €876.0 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Catalyst Pharmaceuticals and its competitors.
Is Catalyst Pharmaceuticals' Total Equity too high?
Catalyst Pharmaceuticals' current Total Equity is €876.0 Mil. Overall, Catalyst Pharmaceuticals has a GF Score™ of 93/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' Total Equity compare to CRNX and NAMS?
Catalyst Pharmaceuticals' Total Equity of €876.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Catalyst Pharmaceuticals and its competitors. Catalyst Pharmaceuticals's current Total Equity is €876.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (FRA:CN2) is currently considered Significantly Overvalued. The stock's GF Value™ is €20.73, compared to a current price of €27.30 — trading 31.7% above its estimated fair value. The current Total Equity is €876.0 Mil. Catalyst Pharmaceuticals' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Catalyst Pharmaceuticals (FRA:CN2), the current Total Equity is €876.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Catalyst Pharmaceuticals (FRA:CN2) Overvalued in 2026?

Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued. The current stock price of €27.30 is trading 31.7% above its estimated GF Value™ of €20.73. GuruFocus considers Catalyst Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:CN2:

  • Total Equity: €876.0 Mil
  • GF Value™: €20.73 vs. price of €27.30 (31.7% above fair value)
  • GF Score™: 93/100 with 6 warning signs

No single metric tells the full story. See the FRA:CN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Catalyst Pharmaceuticals Business Description

Other Exchanges CPRX:USACN2:Germany
Address 355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
93GF Score

Get the complete analysis for FRA:CN2

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.30
Price
€20.73
GF Value